AI to End the Diagnostic Odyssey: Inside ARPA-H's $10M Bet on Patient Data

SAN FRANCISCO, CA – August 31, 2026 – For the over 400 million people worldwide living with a rare genetic disease, the path to a name for their suffering is often a grueling, multi-year ordeal. This “diagnostic odyssey,” a frustrating cycle of specialist visits, inconclusive tests, and frequent misdiagnoses, takes an average of five to seven years. Now, a significant federal investment aims to chart a new, dramatically shorter course.

The Advanced Research Projects Agency for Health (ARPA-H), a federal agency modeled after the legendary DARPA to fund high-risk, high-reward biomedical breakthroughs, has awarded up to $10 million to the AI firm Probably Genetic. The contract, part of ARPA-H's ambitious RAPID program, is designed to scale an innovative platform that turns the traditional diagnostic model on its head, placing power directly into the hands of patients and their caregivers.

“Investments by DARPA, the inspiration for ARPA-H, helped catalyze some of the world's most transformative breakthroughs, including the internet and autonomous vehicles,” said Lukas Lange, CEO of Probably Genetic. “We believe ARPA-H's RAPID program has the potential to do the same for precision medicine.”

Lange’s vision is to assemble the largest AI-ready genetic disease dataset in history, a move he believes will remove the final major bottleneck to making precision medicine accessible to all. If successful, the initiative could redefine the future for one in ten Americans affected by a rare disease.

The Data Bottleneck and a Patient-First Solution

For years, the promise of AI in medicine has been hampered by a critical flaw: the data. Electronic health records (EHRs) are notoriously fragmented, incomplete, and lack the detailed, nuanced information crucial for identifying rare conditions—symptom onset, severity, progression, and subtle morphological features. This data deficit is a primary reason why half of all rare disease patients remain undiagnosed.

Probably Genetic is tackling this challenge by circumventing the traditional system. The company has developed a direct-to-patient model that gathers rich, multi-modal data directly from the source. The process begins with an online symptom assessment tool that uses AI to analyze patient-reported information. If the platform identifies a potential genetic disease, the case is reviewed by a telemedicine physician who can approve an at-home genetic testing kit. The results are then delivered to the patient along with a free genetic counseling session.

This approach doesn't just expand access; it generates a fundamentally different kind of dataset. By integrating patient-reported symptoms, clinical history, and biological data including DNA, the platform creates a structured, deep phenotypic profile that is far more powerful for training AI models. The company has already demonstrated the model's potential, having collected data from over 120,000 patients and partnered with more than 50 patient advocacy groups.

The ARPA-H funding will supercharge this effort, allowing Probably Genetic to deploy its AI-powered data portal across hundreds of rare diseases. This will generate a large, diverse, and deeply characterized dataset that will serve as a cornerstone for RAPID's national-scale data ecosystem.

A High-Risk, High-Reward Federal Bet

The decision by ARPA-H to invest in this platform reflects the agency's core mission: to fund revolutionary advances that traditional research or commercial activity cannot readily accomplish. The Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program was specifically created to end the diagnostic odyssey by combining novel AI with multimodal data.

“Rare disease diagnosis remains one of medicine's most difficult and under-addressed challenges,” said Scott Gorman, RAPID Program Manager at ARPA-H. “Through our RAPID program, ARPA-H is tackling this challenge by combining novel AI approaches with multimodal data to enable cross-disease detection at a speed and scale not previously possible — while also generating new insights to accelerate treatment development.”

This federal backing is a powerful endorsement of a patient-driven approach. It acknowledges that solving the rare disease puzzle requires not only advanced algorithms but also a new, more collaborative way of gathering and sharing information. In building this massive dataset, the project must also navigate the complex ethical landscape of data privacy. Probably Genetic has stated that all data will be de-identified and used only for purposes to which patients give explicit, informed consent, a critical component for building trust within the patient community.

From Diagnosis to Drug Discovery

The impact of this initiative extends far beyond shortening the diagnostic journey. The comprehensive, AI-ready dataset it creates is poised to become an invaluable resource for the entire biopharmaceutical industry. By linking real-world evidence to underlying disease biology, the data will provide drug developers with the insights needed to identify new therapeutic targets, stratify patients for clinical trials, and design more effective studies.

This is a game-changer in a field where progress is often slow and prohibitively expensive. In the current landscape, other entities are also leveraging AI, from hospital-based systems that scan EHRs to flag potential cases to AI models that repurpose existing drugs for new diseases. However, Probably Genetic’s key differentiator is its ability to build an unprecedented dataset at a global scale, directly powered by the very individuals affected by these conditions.

This vast repository of patient-consented information could unlock new understandings of disease progression and create opportunities for developing personalized treatments. It aligns with ARPA-H's broader vision, which includes programs aimed at creating platform-based genetic medicines that can be reused across multiple therapies. By building the foundational data layer, Probably Genetic and ARPA-H are not just helping find answers for patients today; they are building the infrastructure to accelerate the discovery of the cures of tomorrow.